Results 181 to 190 of about 4,076 (204)
Some of the next articles are maybe not open access.
Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects
Drug Metabolism and Disposition, 2008This study was designed to investigate the human absorption, disposition, and mass balance of (14)C-brivaracetam, a novel high affinity SV2A ligand with potent anticonvulsant activity. Six healthy male subjects received a single p.o. dose of (14)C-brivaracetam (150 mg, 82 microCi, or 3.03 MBq).
Maria Laura, Sargentini-Maier +3 more
openaire +2 more sources
A Mitochondrial Role of SV2a Protein in Aging and Alzheimer’s Disease: Studies with Levetiracetam
Journal of Alzheimer's Disease, 2016Aberrant neuronal network activity associated with neuronal hyperexcitability seems to be an important cause of cognitive decline in aging and Alzheimer’s disease (AD). Out of many antiepileptics, only levetiracetam improved cognitive dysfunction in AD patients and AD animal models by reducing hyperexcitability.
Carola, Stockburger +7 more
openaire +2 more sources
Imaging the Effect of Ketamine on Synaptic (SV2A) Density
Biological Psychiatry, 2021Sophie Holmes +16 more
openaire +1 more source
Implication of the SV2A protein in epilepsy: preclinical studies
2019This PhD thesis deals with epilepsy and, in particular, with the role the Synaptic Vesicle 2A (SV2A) protein plays on the development and severity of this disease. Epilepsy is a group of neurodegenerative diseases whose most notable feature is the presence of spontaneous and recurrent brain seizures. Despite the extensive efforts made to treat epilepsy,
openaire +1 more source
Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy.
Current opinion in investigational drugs (London, England : 2000), 2008UCB SA was developing the high-affinity synaptic vesicle glycoprotein 2A ligand, seletracetam, an analog of levetiracetam, for the potential oral treatment of epilepsy. Phase II epilepsy trials were underway, but in July 2007, the company stated that development of seletracetam had been put on hold and it is unknown whether planned phase IIb/III trials
openaire +1 more source
Structural insights into SV2A and the mechanism of racetam anticonvulsants
Nature Structural & Molecular BiologyMazdak M. Bradberry, Edwin R. Chapman
openaire +2 more sources
Structural Basis of Botulinum Neurotoxin Serotype A1 Binding to Human SV2A or SV2C Receptors
Chemico-Biological Interactions, 2023Jacques Fantini +2 more
exaly
Application of SV2A PET in neurodegenerative disorders
SCIENTIA SINICA VitaeDaJi CHEN, Hong JIANG
openaire +1 more source